149 related articles for article (PubMed ID: 10513855)
21. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients.
Lundmark J; Wålinder J; Alling C; Manniche PM; Dalgaard L
Eur Neuropsychopharmacol; 1994 Mar; 4(1):1-6. PubMed ID: 7515737
[TBL] [Abstract][Full Text] [Related]
22. Paroxetine-induced somnambulism.
Kawashima T; Yamada S
J Clin Psychiatry; 2003 Apr; 64(4):483. PubMed ID: 12716257
[No Abstract] [Full Text] [Related]
23. Paroxetine-induced angioedema and tongue swelling.
Mithani H; Hurwitz TA
J Clin Psychiatry; 1996 Oct; 57(10):486. PubMed ID: 8909336
[No Abstract] [Full Text] [Related]
24. Hypersensitivity to paroxetine.
Mera MT; Pérez BV; Fernández RO; Iglesias JF
Allergol Immunopathol (Madr); 2006; 34(3):125-6. PubMed ID: 16858890
[TBL] [Abstract][Full Text] [Related]
25. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients.
Elliott AJ; Uldall KK; Bergam K; Russo J; Claypoole K; Roy-Byrne PP
Am J Psychiatry; 1998 Mar; 155(3):367-72. PubMed ID: 9501747
[TBL] [Abstract][Full Text] [Related]
26. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
[TBL] [Abstract][Full Text] [Related]
27. Hyponatraemia associated with the use of a selective serotonin-reuptake inhibitor in an older patient.
Schouten WE; Sepers JM
Age Ageing; 2001 Jan; 30(1):94. PubMed ID: 11322690
[No Abstract] [Full Text] [Related]
28. Withdrawal syndromes after paroxetine and sertraline discontinuation.
Fava GA; Grandi S
J Clin Psychopharmacol; 1995 Oct; 15(5):374-5. PubMed ID: 8830071
[No Abstract] [Full Text] [Related]
29. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
30. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects.
Geretsegger C; Böhmer F; Ludwig M
Int Clin Psychopharmacol; 1994; 9(1):25-9. PubMed ID: 8195578
[TBL] [Abstract][Full Text] [Related]
31. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.
Deakin JB; Rahman S; Nestor PJ; Hodges JR; Sahakian BJ
Psychopharmacology (Berl); 2004 Apr; 172(4):400-8. PubMed ID: 14666399
[TBL] [Abstract][Full Text] [Related]
32. Paroxetine treatment of trichotillomania in an adolescent.
Block C; West SA; Baharoglu B
J Child Adolesc Psychopharmacol; 1998; 8(1):69-71. PubMed ID: 9639081
[TBL] [Abstract][Full Text] [Related]
33. Antidepressant treatment and global tests of coagulation and fibrinolysis.
Lederbogen F; Weber B; Colla M; Heuser I; Deuschle M; Dempfle CE
J Clin Psychiatry; 2001 Feb; 62(2):130. PubMed ID: 11247103
[No Abstract] [Full Text] [Related]
34. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
35. Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine.
Munno D; Sterpone S; Fania S; Cappellin F; Mengozzi G; Saroldi M; Bechon E; Zullo G
Panminerva Med; 2013 Dec; 55(4):377-84. PubMed ID: 24434345
[TBL] [Abstract][Full Text] [Related]
36. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique.
Bordet R; Thomas P; Dupuis B
Am J Psychiatry; 1998 Oct; 155(10):1346-51. PubMed ID: 9766765
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine.
Gilmor ML; Owens MJ; Nemeroff CB
Am J Psychiatry; 2002 Oct; 159(10):1702-10. PubMed ID: 12359676
[TBL] [Abstract][Full Text] [Related]
38. Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial.
Rocca P; Calvarese P; Faggiano F; Marchiaro L; Mathis F; Rivoira E; Taricco B; Bogetto F
J Clin Psychiatry; 2005 Mar; 66(3):360-9. PubMed ID: 15766303
[TBL] [Abstract][Full Text] [Related]
39. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study.
Meyer JH; Kapur S; Eisfeld B; Brown GM; Houle S; DaSilva J; Wilson AA; Rafi-Tari S; Mayberg HS; Kennedy SH
Am J Psychiatry; 2001 Jan; 158(1):78-85. PubMed ID: 11136637
[TBL] [Abstract][Full Text] [Related]
40. Recognition and treatment of serotonin syndrome.
Frank C
Can Fam Physician; 2008 Jul; 54(7):988-92. PubMed ID: 18625822
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
